Resource Utility {#S1}
================

Human induced pluripotent stem cells (hiPSCs) from CADASIL patients may provide a powerful tool for studying the effects of NOTCH3 on human development and the pathophysiology of CADASIL disease.

Resource Details {#S2}
================

Cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is an inherited disease caused by mutations in the *NOTCH3* gene located on chromosome 19. These autosomal dominant mutations are nonsynonymous substitutions, resulting in the addition or deletion of a cysteine residue within the NOTCH3 extracellular domain coding sequences ([@R5]; and [@R2]). This disease is characterized by migraines, white matter changes, recurrent strokes and early onset dementia through a largely unknown mechanism that is thought to primarily affect the small blood vessels in the brain. ([@R3]; [@R4]).

The five CADASIL patients were enrolled into one of our NHLBI clinical protocols (16-H-0132). Information regarding clinical onset was obtained using a standard clinical interview format. All 5 patients have been found to have heterozygous missense mutations in the gene *NOTCH3* located on chromosome 19. The mutations result in the addition or deletion of a cysteine residue within epidermal growth factor (EGF)-like repeats of NOTCH3 extracellular domain which is responsible for CADASIL disease. The details of genetic information are shown in [Table 1](#T1){ref-type="table"}, and [Supplement file 1](#SD1){ref-type="supplementary-material"}. The patient NIHTVBi004-A (HT405A) has been found to have heterozygous missense mutations in the gene NOTCH3 (c.994C\>*T*; p.Arg332Cys) which affects the calcium binding domain in EGF8; the patient NIHTVBi005-A (HT406D) has been found to have heterozygous missense mutations in the gene NOTCH3 (c.505C \> *T*; p.Arg169Cys) which affects the calcium binding domain in EGF4; the patient NIHTVBi006-A (HT407D) has been found to have heterozygous missense mutations in the gene *NOTCH3* (c.697T \> G; p.Cys233Gly) which affects the protein binding domain of EGF5; the patient NIHTVBi007-A (HT409A) has been found to have heterozygous missense mutations in the gene *NOTCH3* (c.665G \> A; p.Cys222Tyr) which affects the protein binding domain of EGF5; and the patient NIHTVBi008-A (HT454D) has been found to have heterozygous missense mutations in the gene *NOTCH3* (c.1364G \> *A*; p.Cys455Tyr) which affects the calcium binding domain in EGF11. Blood samples were collected at the NIH Clinical Center. Using a Sendai viral vector delivery system expressing four transcription factors (*OCT4, SOX2, KLF4* and *C-MYC*), we successfully generated hiPSC lines carrying each of the five *NOTCH3* mutations. The hiPSCeCADASIL lines maintained typical morphologies and expressed the common pluripotency markers OCT4, NANOG, TRA-1--60, SSEA4 and SOX2, as shown by immunocytochemistry ([Fig. 1A](#F1){ref-type="fig"}), flow cytometry ([Fig. 1B](#F1){ref-type="fig"}) and/or real-time (RT)-qPCR ([Fig. 1D](#F1){ref-type="fig"}). HiPSCeCADASIL genotyping confirmed NOTCH3 mutations corresponding to each parental cell line ([Fig. 1C](#F1){ref-type="fig"}). To test the differentiation potential of these cell lines, we performed a monolayer differentiation assay to drive cells towards the three germ layers *in vitro*. We determined the marker gene expression for the endoderm (*AFP*), ectoderm (*NES*) and mesoderm (*RUNX1*) by RT-qPCR, which showed up-regulated expression levels in differentiating cells at day 7 compared to undifferentiated hiPSCeCADASIL cells ([Fig. 1D](#F1){ref-type="fig"}). All five iPSC lines demonstrated chromosomal stability and normal karyotype with G-banding ([Fig. 1E](#F1){ref-type="fig"}). Short tandem repeat (STR) profiles indicated that all hiPSCeCADASIL lines matched their parental blood cells completely in 15 amplified STR loci ([Supplementary file 2](#SD1){ref-type="supplementary-material"}). All cell cultures were routinely tested for *Mycoplasma* contamination and were found to be *Mycoplasma* free ([Supplementary file 3](#SD1){ref-type="supplementary-material"}). The iPSCs were free of Sendai virus after the 15th passage as shown by PCR ([Supplementary file 4](#SD1){ref-type="supplementary-material"}). In conclusion, hiPSCeCADSASIL lines exhibited pluripotent potential for self-renewal, proliferation and differentiation. To the best of our knowledge, this is the first published study in which hiPSC lines were generated from individuals with the CADASIL carrying *NOTCH3* mutations ([Table 2](#T2){ref-type="table"}).

1.. Materials and methods {#S3}
=========================

1.1.. Subjects and study approval {#S4}
---------------------------------

iPSCs were generated from blood samples obtained from five CADASIL patients carrying a *NOTCH3* mutation. This study was approved by the NHLBI's Institutional Review Board, and samples were collected after obtaining informed written consent.

1.2.. Generation and culture of human iPSCs from peripheral blood mononuclear cells (PBMCs) {#S5}
-------------------------------------------------------------------------------------------

The PBMCs were isolated from blood samples through density gradient centrifugation via Ficoll-Paque following the manufacturer's protocol. Approximately 3 to 5 × 10^5^ PBMCs were plated into one well of a 6-well plate within Erythroid Expansion Medium (Stemcell Technologies) for expansion of erythroid progenitor cells. Half of the medium was replaced with fresh medium every other day. At day 9\~10, the cells were transduced with CytoTune™ 2.0 Sendai reprogramming vectors (Invitrogen). After three days in culture, the cells were collected and seeded into Matrigel (Corning) pre-coated plates supplemented with TesR-E7 medium (Stemcell Technologies) for 10\~15 days. After which the medium was replaced with TesR-E8 medium (Stemcell Technologies) until day 21. Once iPSC colonies emerged in culture, they were picked up and transferred onto fresh Matrigel pre-coated plate for further expansion ([@R1]).

1.3.. Immunofluorescent staining and flow cytometry analysis {#S6}
------------------------------------------------------------

iPSCs were fixed with 4% paraformaldehyde and stained for immunohistochemistry. Briefly, cells were incubated with primary antibodies against SSEA4 ([Table 3](#T3){ref-type="table"}) at 4 C overnight. After washes in PBS, they were incubated with fluorophore-tagged secondary antibodies at room temperature for 1 h After PBS washes, the nuclei were then stained with DAPI and images were captured using a fluorescence microscope (Zeiss).

For FACS analysis, iPSCs were digested to a single cell suspension by incubation with Trypsin-EDTA (Invitrogen). Following by fixation and permeabilization, the cells were stained with antibodies. Analysis was performed on a MACSQuant Flow Cytometer (Miltenyi) and the results were analyzed using FlowJo software (FlowJo, LLC).

1.4.. Monolayer differentiation assay {#S7}
-------------------------------------

To assess hiPSCeCADASIL ability to differentiate *in vitro*, cell cultures were dissociated into small clumps with 0.5 μM EDTA and cultured on Matrigel Precoated Plates (Corning) with differentiation medium consisting of 90% KnockOut DMEM, 10% FBS, 2 mM ~L~-gluta-mine, 0.1 mM non-essential amino acids and 0.1 mM 2-mercaptoethanol (Invitrogen). After seven days, cells were harvested for further analysis.

1.5.. Gene expression analysis {#S8}
------------------------------

The total RNA was isolated by using RNeasy Mini Kits (Qiagen). Endogenous mRNA expression levels of *NANOG, SOX2, AFP, NES*, and *RUNX1* were determined in iPSCs and in differentiating cells at day 7 ([Fig. 1D](#F1){ref-type="fig"}). RT-qPCR was performed by using SYBR Green Premix on a Real-Time PCR Detection System (Bio-Rad). Assays were run in triplicate and the results were normalized to 18S ribosomal RNA expression. Primers used for RT-qPCR are shown in [Table 3](#T3){ref-type="table"}. After 15 passages, iPSC lines were tested for Sendai virus (SeV) residues by using RT-PCR with the primers indicated in [Table 2](#T2){ref-type="table"}.

1.6.. Karyotyping assay {#S9}
-----------------------

The karyotype of hiPSCeCADASIL was evaluated by the WiCell Research Institute using G-banding metaphase karyotype analysis.

1.7.. DNA sequencing and STR analysis {#S10}
-------------------------------------

Genomic DNA was extracted by using DNeasy Blood & Tissue Kit (Qiagen). To amplify the corresponding mutation position in *NOTCH3*, PCR was performed with specific primers ([Table 3](#T3){ref-type="table"}). Following purification, the PCR products were sent to Eurofins Scientific for sequencing.

STR analysis was performed by WiCell Research Institute, which generated a STR profile via the Promega Powerplex^®^ 16 System to verify STR polymorphisms for 15 loci plus amelogenin in genomic DNA extracted from iPSCs and their parental fibroblasts.

1.8.. Mycoplasma detection {#S11}
--------------------------

To validate that the hiPSCeCADASIL cultures were *Mycoplasma* free, mycoplasma analysis was performed using the MycoAlert™ Mycoplasma Detection Kit (Lonza, LT27--224). Briefly, the culture media was collected after culturing for 48 h while the confluency of cells was at last 80%. As according to manufacturer's protocol, 100 μl of clearer supernatant was used as the test sample to screen for mycoplasma contamination. The absence of mycoplasma contamination was confirmed in all hiPSCeCADASIL culture tested ([Supplement file 2](#SD1){ref-type="supplementary-material"}).

Supplementary Material {#SM1}
======================

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.scr.2020.101821](10.1016/j.scr.2020.101821).

![Characterization of human iPSC lines derived from five CADASIL patients with a *NOTCH3* mutation. (A) iPSCs were cultured to passage 15 on a feeder-coated plate. Phase contrast images of iPSC lines derived from five CADASIL patients with a *NOTCH3* mutation (HT405A, HT406D, HT407D, HT409A and HT454D) (top column). Expression of pluripotent markers SSEA4 was analyzed by immunofluorescence; DAPI staining of cell nuclei in blue (bottom columns) (all scale bars: 100 μm). (B) The expression level of pluripotent markers (SSEA4, TRA-1--60, Oct4, Sox2, and Nanog) was quantitative analysis by Flow Cytometry Analysis. (C) PCR and DNA sequencing identified mutations in *NOTCH3* in the iPSC lines from the five patients (red arrows). (D) Expression of pluripotent genes (*NANOG, SOX2*, and *OCT3/4*) was confirmed in all hiPSC lines derived from CADASIL patients as assessed by RT-qPCR (black bar). All five hiPSC lines from CADASIL patients were able to differentiate into three germ layers using monolayer differentiation in vitroat day 7, as shown by gene expression of *AFP, NESTIN* and *RUNX1* (gray bar). Data are represented as means ± SEM relative to mRNA levels. (E) All five hiPSC lines from CADASIL patients showed a normal karyotype with G-band analysis.](nihms-1599551-f0001){#F1}

###### 

Summary of patients with a CADASIL disease.

  iPSC line names   Abbreviation in figures   Gender   Age (years)   Ethnicity            Genotype of locus                      Disease
  ----------------- ------------------------- -------- ------------- -------------------- -------------------------------------- ---------
  NIHTVBi004-A      HT405A                    M        43            White/non-hispanic   Notch 3, C.994C \> *T;* p.Arg332Cys    CADASIL
  NIHTVBi005-A      HT406D                    F        61            White/non-hispanic   Notch 3, C.505C \> *T;* p.Argl69Cys    CADASIL
  NIHTVBi006-A      HT407D                    M        43            White/non-hispanic   Notch 3, C.697T \> *G;* p.Cys233Gly    CADASIL
  NIHTVBi007-A      HT409A                    F        62            White/non-hispanic   Notch 3, C.665G \> *A;* p.Cys222Tyr    CADASIL
  NIHTVBi008-A      HT454D                    M        50            White/non-hispanic   Notch 3, C.1364G \> *A;* p.Cys455Tyr   CADASIL

###### 

Characterization and validation.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Classification                        Test                                                       Result                                                                                                                     Data
  ------------------------------------- ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------
  Morphology Phenotype                  Phase-contrast microscope\                                 Normal\                                                                                                                    [Fig. 1A](#F1){ref-type="fig"}\
                                        Qualitative analysis (immunofluorescence staining)\        Expression of pluripotency markers: Oct4, Nanog, SSEA4 and Tra-1--60\                                                      [Fig. 1A](#F1){ref-type="fig"}\
                                        Quantitative analysis (flow cytometry analysis, RT-qPCR)   Expression of pluripotency markers: *S0X2* and *NANOG*                                                                     [Fig. 1B](#F1){ref-type="fig"}, [1D](#F1){ref-type="fig"}

  Genotype                              Karyotype (G-banding) and resolution                       46.XX or 46.XY; resolution 450--500 bands                                                                                  [Fig. 1E](#F1){ref-type="fig"}

  Identity                              Microsatellite PCR OR STR analysis                         Not performed 15 sites tested, 100% match                                                                                  N/A [Supplementary file 2](#SD1){ref-type="supplementary-material"}

  Mutation analysis (IF APPLICABLE)     DNA sequencing\                                            Notch 3, Chromosome 19, GRch38\                                                                                            [Fig. 1C](#F1){ref-type="fig"}\
                                        Southern blot OR WGS                                       Not performed                                                                                                              N/A

  Microbiology and virology             *Mycoplasma* testing by luminescence                       Negative                                                                                                                   [Supplementary file 3](#SD1){ref-type="supplementary-material"}

  Differentiation potential             Monolayer differentiation assay                            Differentiating cells are expression of *RUNX1, AFP,* and *NES;* iPSCs were able to differentiate into three germ layers   [Fig. 1D](#F1){ref-type="fig"}

  Donor screening (OPTIONAL)            HIV1 + HIV2, hepatitis B virus, hepatitis C virus          Not performed                                                                                                              N/A

  Genotype additional info (OPTIONAL)   Blood group genotyping\                                    Not performed\                                                                                                             N/A\
                                        HLA tissue typing                                          Not performed                                                                                                              N/A
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Reagents.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Antibodies used for immunocytochemistry and *Flow Cytometry Analysis*                                                                                                                    
  ----------------------------------------------------------------------- ------------------------------------------------------------------------ -------- ------------------- ---------- ---------------
  Primary antibodies                                                      Mouse anti-SSEA4\                                                        1:100\   MilliporeSigma\     MAB4304\   AB_177,629\
                                                                          Alexa Fluor 488 anti-SSEA4 Antibody\                                     1:10\    BioLegend\          330,412\   AB_l,089,198\
                                                                          PE anti-TRA-1--60 Antibody\                                              1:10\    BioLegend\          330,610\   AB_2,119,065\
                                                                          Alexa Fluor 488 anti-SOX2 Antibody\                                      1:10\    BioLegend\          656,110\   AB_2,563,957\
                                                                          Alexa Fluor 488 anti-OCT4 Antibody\                                      1:10\    BioLegend\          653,708\   AB_2,563,184\
                                                                          Alexa Fluor 647 anti-NANOG Antibody                                      1:10     BioLegend           674,210    AB_2,650,619

  Secondary antibodies                                                    Alexa Fluor 488 Donkey anti-mouse                                        1:300    Life Technologies   A21202     AB_141,607

  Primers used for RT-qPCR and PCR                                                                                                                                                         

  Target                                                                  Forward/reverse primer (5' -- 3')                                                                                

  *NANOG*                                                                 AGG GAA ACA ACC CAC TTC T/CCT TCT GCG TCA CAC CAT T                                                              

  *S0X2*                                                                  CCC AGC AGA CTT CAC ATG T/CCT CCC ATT TCC CTC GTT TT                                                             

  *AFP*                                                                   AGC TTG GTG GAT GAA AC/CCC TCT TCA GCA AAG CAG AC                                                                

  *NESTIN*                                                                GCG TTG GAA CAG AGG TTG GA/TGG GAG CAA AGA TCC AAG AC                                                            

  *RUNX1*                                                                 CTG CCC ATC GCT TTC AAG GT/GCC GAG TAG TTT TCA TTG CC                                                            

  *Sev*                                                                   GGA TCA CTA GGT GAT ATC GAG C/ACC AC JA CAA GAG TTT AAG AGA TAT GTA TC                                           

  *Sev c-MYC*                                                             TAA CTG ACT AGC AGG CTT GTC G/TCC AC A TAC AGT CCT GGA TGA TG                                                    

  *N0TCH3 HT405A/407D*                                                    ACG ACT GTG CCT GTC TTC CT/TGC CCA GCC TAG CAT AAT CT                                                            

   *N0TCH3*                                                               GGG GTG TGG TCA GTC CTA AA/CTG ACC CTC AAA CCC TAG CA                                                            

   *HT406D/409A*                                                          GGA GCT CCA TCG TCT GTG A/ACC TCC TTC CAG GCT TCA GT                                                             

   *N0TCH3*                                                                                                                                                                                

   *HT454D*                                                                                                                                                                                

  *β-ACTIN*                                                               GAG AAG ATG ACC CAG ATC ATG TTT/GGC AGC TCG TAG CTC TTC TCC A                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Resource Table

  -------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Unique stem cell lines identifier      NIHTVBi004-A\
                                         NIHTVBi005-A\
                                         NIHTVBi006-A\
                                         NIHTVBi007-A\
                                         NIHTVBi008-A

  Alternative names of stem cell lines   HT405A\
                                         HT406D\
                                         HT407D\
                                         HT409A\
                                         HT454D

  Institution                            National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, USA

  Contact information of distributor     Manfred Boehm; HYPERLINK "mailto: <boehmm@nhlbi.-nih.gov>

  Type of cell lines                     iPSC

  Origin                                 Human

  Cell Source                            Peripheral blood mononuclear cells

  Clonality                              Clonal cell lines

  Method of reprogramming                Sendai vectors containing the transcription factors Oct-4, Klf4, Sox2 and c-MYC

  Multiline rationale                    Lines derived from the five individuals

  Gene modification                      Yes

  Type of modification                   Hereditary

  Associated disease                     None

  Gene/locus                             N0TCH3, Chromosome 19, GRch38.pl2

  Method of modification                 N/A

  Name of transgene or resistance        N/A

  Inducible/constitutive system          N/A

  Date archived/stock date               December 2013

  Cell line repository/bank              N/A

  Ethical approval                       National Institutes of Health Ethics Committee (Approval Number: 16-H-0132)
  -------------------------------------- -----------------------------------------------------------------------------------------------------------------
